An ongoing dialogue on HIV/AIDS, infectious diseases,
March 10th, 2009
Unwelcome Visitor: Cost of HIV Meds
Those of us who practice HIV medicine in Taxachusetts (warning, click link at your peril) live a pretty charmed life, at least so far as getting HIV medications paid for. Due to an incredibly generous AIDS Drug Assistance Program (ADAP), rare is the patient who faces financial barriers getting his or her drugs.
(By the way, we abbreviate it “HDAP” here, not ADAP. And we treat early syphilis with two shots of penicillin, not one. And we voted for McGovern. And we drive on the left.)
But the recent downturn in the economy has changed this usually comfortable situation in the Bay State.
A patient of mine called to tell me that his co-pay for a 3 month supply of his antivirals is now nearly $2000. Another one has simply stopped coming to appointments, as his wife’s insurance has such a large deductible that he will only agree to blood tests, not an actual office visit. A third asked me whether he would be better off stopping enoxaparin or his HIV meds, since he couldn’t afford both.
I am sure things are much worse in other States — after all, Houston’s Joe Gathe initially tried lopinavir/r monotherapy since he reasoned that some ART was better than none, and his patients couldn’t afford triple-therapy.
Where is this headed? It’s tough to make predictions (especially about the future), but I suspect that when 3TC and saquinavir become generic, we might be turning to them more often than we’d previously thought.
Categories: Health Care, HIV, Infectious Diseases, Patient Care
Tags: 3tc, ADAP, aids drug assistance program, Cost, financial barriers, HDAP, HIV, hiv medications, HIV medicine, lopinavir, monotherapy, saquinavir, Taxachusetts
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
- Ivermectin for COVID-19 — Breakthrough Treatment or Hydroxychloroquine Redux?
- COVID-19 Vaccine Frequently Asked Questions
- Common Questions About the Shingles Vaccine — Answered Here!
- After Ivermectin Controversy, A COVID-19-Free ID Link-o-Rama
- Bamlanivimab for COVID-19 — Hard to Pronounce, Even Harder to Give
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- Rapid, Inexpensive Home Testing for COVID-19 May Get Us Out of This Mess Before a Vaccine (72)
-
Subscribe to HIV and ID Observations via Email
NEJM Journal Watch — Recent Infectious Disease Articles
- Allergic Reactions to the Pfizer-BioNTech COVID-19 Vaccine: An Early Report
- Yellow Fever Virus Vaccine: Stretching the Supply
- For SARS-CoV-2 Detection, Saliva Performed as Well as Nasopharyngeal Swabs
- Our Recent Coverage of COVID-19
- Exploring Risk for Invasive Pulmonary Mold Infection in Severe COVID-19
-
Physician's First WatchToday's breaking medical news
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff COVID-19 CROI cure darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster